Infant Bacterial Therapeutics ABFRA:9IB +0.48%13 Net Current Asset Value is €0.51 as of Mar. 2026, which is 100% below its 10-year median of 3.13. GuruFocus rates FRA:9IB with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 78.54% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Infant Bacterial Therapeutics AB's Net Current Asset Value or its related term are showing as below:
FRA:9IB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.73 Med: 3.13 Max: 12.58
Current: 12.58
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Infant Bacterial Therapeutics AB was 12.58. The lowest was 1.73. And the median was 3.13.
FRA:9IB's Price-to-Net-Current-Asset-Value is ranked worse than 78.54% of 946
companies
in the Biotechnology industry
Industry Median: 4.955
vs FRA:9IB: 12.58
Infant Bacterial Therapeutics AB (FRA:9IB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Infant Bacterial Therapeutics AB Net Current Asset Value Related Terms
Infant Bacterial Therapeutics AB Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB Net Current Asset Value Chart
FRA:9IB vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.51 mean?
Infant Bacterial Therapeutics AB (FRA:9IB) has a Net Current Asset Value of €0.51 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Infant Bacterial Therapeutics AB and its competitors. This is 84% below median its historical median of 3.13. Over the past decade, Infant Bacterial Therapeutics AB's Net Current Asset Value has ranged from 1.73 to 12.58. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #743 out of 946 companies in the Biotechnology industry, placing it in the top 78.5%.
Is Infant Bacterial Therapeutics AB's Net Current Asset Value too high?
Infant Bacterial Therapeutics AB's current Net Current Asset Value of €0.51 is 84% below median its 10-year median of 3.13. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 12.58. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #743 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #743 out of 946 companies for Net Current Asset Value. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median Net Current Asset Value is 4.96. Historically, Infant Bacterial Therapeutics AB's own Net Current Asset Value has ranged from 1.73 to 12.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current Net Current Asset Value is €0.51, which is 84% below median its own 10-year median of 3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (FRA:9IB) has a current Net Current Asset Value of €0.51. The current Net Current Asset Value is €0.51, which is 84% below median its 10-year median of 3.13. Infant Bacterial Therapeutics AB's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (FRA:9IB), the current Net Current Asset Value is €0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score
Get the complete analysis for FRA:9IB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9IB has been successfully added to your 
